5-MeO-NBnT, also known as N-benzyl-5-methoxytryptamine or as 5-MeO-T-NB, is a serotonin receptor agonist of the tryptamine and 5-methoxytryptamine families related to 5-MeO-NMT.
5-MeO-NBnT binds to the serotonin 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, and 5-HT<sub>2C</sub> receptors (K<sub>i</sub> = 5.3âÂÂ55nM, 16.6nM, and 95.5âÂÂ370nM, respectively). It was assessed and found to be a potent partial agonist of the serotonin 5-HT<sub>2A</sub> receptor ( = 20.4âÂÂ100nM; = 30âÂÂ63%) and full agonist of the serotonin 5-HT<sub>2C</sub> receptor ( = 14.5nM; = 113%). The drug was not evaluated in terms of effects in animals.
The chemical synthesis of 5-MeO-NBnT has been described.
Analogues of 5-MeO-NBnT include N-benzyltryptamine (NBnT), 4-HO-NBnT, 5-MeO-NBOMeT, and 5-MeO-NB3OMeT, among others. It is also analogous to N-benzylphenethylamines, for instance 25-NB (NBOMe), 25B-NB (N-benzyl-2C-B), and 25I-NBOMe.
5-MeO-NBnT was first described in the scientific literature by Keijiro Takagi and colleagues by 1969.